Abzena

During Bone Cancer Awareness Month, we at Abzena are committed to advancing innovative therapeutic solutions to improve patient outcomes. Bone cancer is often considered to be rare and is frequently granted orphan drug designation, emphasizing the critical need for targeted treatments. Our work with antibody-drug conjugates (ADCs), including antibody radio-conjugates, exemplifies our dedication to creating therapies for orphan indications that enhance efficacy and minimize side effects, particularly for those with limited treatment options. Raising awareness and supporting research for bone cancer is vital. Together, we can make a difference in the lives of patients and their families in the rare disease community. #BoneCancerAwareness #OrphanDrugs #Oncology #ADCCDMO #RareDisease #PatientCare

At Abzena, we are focused on rapidly moving medicines forward by providing best-in-class, fully integrated CDMO + CRO services that streamline and de-risk the development pathway for complex #biologics and bioconjugates (#ADCs).    Our state-of-the-art facilities and expert scientific teams ensure high-quality, scalable, and efficient solutions for our customers that span from concept through commercialization.    By combining advanced technologies with decades of experience, we enable faster delivery of life-changing medicines to patients in need.   Discover how our comprehensive capabilities can help you achieve your next target inflection point faster- https://lnkd.in/gJiywnC2   #ADCCDMO #CDMO #CRO #DrugDevelopment #DrugSubstance

Our latest case study shows stochastic lysine-based #conjugation as a robust and scalable methodology to produce Antibody-drug Conjugates (#ADCs). The study details our advanced techniques and methodologies, demonstrating Abzena's commitment to delivering solutions in biopharmaceutical manufacturing. Access the full case study here: https://lnkd.in/eZdZevtu #ADCCDMO #DrugDevelopment #CDMO #CRO #ProcessDevelopment #ScalingProduction

Our latest blog features Eric Miller, Ian Glassford, PhD, MBA, and Louise Duffy discussing the important role that rapid analytics and platform strategies can play in accelerating novel #biotherapeutics toward the clinic.    Rapid analytics can enhance #manufacturability and reduce degradation, thus expediting toxicological material generation and ensuring a more robust formulation for use in the clinic.    At Abzena, our streamlined #analytical processes reduce risks, and accelerate timelines from candidate selection to clinical trials by leveraging standardized methods and advanced computational tools. We integrate data from all stages of development to provide actionable insights, support #IND applications, and speed up the transition from preclinical to Phase I and beyond    Access our blog to discover how Abzena’s analytical approach can expedite your biologic's development pathway: Rapid Analytics: https://lnkd.in/eamwSiuV #DrugDevelopment #CDMO #CRO #RapidAnalytics #PlatformStrategies 

Effective drug development often hinges on reliable and precise bioassays and analytics. In the early phases, ensuring the accuracy of these analyses is crucial for promising candidates to progress through the pipeline. At Abzena, we address these challenges with our comprehensive suite of early-phase bioassays and analytical services. Our state-of-the-art technologies and expert team provide robust solutions to accurately characterize and quantify biomolecules, ensuring high standards of precision and reliability. Our services cover a range of critical activities, including assay development, validation, and routine sample analysis. By integrating innovative methodologies, we enhance the data quality that underpins key decision-making in drug development. Explore how our early-phase bioassays and analytics can streamline your project from discovery to clinical development. Access our latest info sheet to learn more: https://lnkd.in/ee6FDKsc #Bioassays #Analytics #CDMO #CRO #DrugDevelopment #Biotechnology #Abzena

Antibody-drug Conjugates (#ADCs) are redefining oncology therapeutics by offering targeted delivery of cytotoxic agents directly to cancer cells, thereby minimizing systemic toxicity. In a recent article in Drug Target Review, Abzena's Petra Dieterich, DPhil, MBA, Ian Glassford, PhD, MBA, and Jeffrey C. Mocny, Ph.D. discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors explore the need for further data to improve understanding and refine drug design with safety and efficacy in mind and the role that linker technologies and site-specific conjugation play in optimizing the therapeutic window of ADCs. Access the article to learn more about these promising therapeutics: https://lnkd.in/epRyCVnJ #CancerTreatment #Oncology #Biotechnology #TherapeuticAdvancements #CDMO #CRO

Access our recent case study with Sartorius focused on streamlining the conjugation of an Oligo-mAb program. From developing a robust process #development and #manufacturing strategy to utilizing membrane chromatography for endotoxin removal - see how we were able to expedite the conjugation process for this complex program. Click here to access the case study: https://lnkd.in/gFnkBD7p #CRO #CDMO #oligo #drugdevelopment #biopharmaceutical

Achieving your Target Product Profile (TPP) for your complex #biologic or #bioconjugate requires a robust and comprehensive approach to formulation development. Having delivered over 1400+ programs, our expert scientists prioritize solubility, delivery, safety, and sustained stability to ensure that your biopharmaceutical successfully transforms from a concept into a market-ready therapeutic.   Our flexible and customizable approach coupled with advanced technologies such as mass spectrometry, particle size assessment, and UPLC/HPLC systems, helps to ensure a streamlined and de-risked path to the clinic and beyond. From initial pre-formulation studies and generation of a formulation to support toxicology and first-in-human trials through to clinical in-use studies, formulation optimization, and device interaction studies - our comprehensive suite of services enables us to support your program throughout its entire lifecycle all under a single organization.   Access our latest info sheet to discover how our formulation development expertise can rapidly progress your project to its next target inflection point: https://lnkd.in/ef7JX5Hv   #FormulationDevelopment #CDMO #CRO #DrugDevelopment

Scaling-up a #biologic from clinical development to commercial production can present it's own set of unique challenges and possible time constraints. At Abzena, our comprehensive and fully integrated capabilities de-risks and streamlines the path to commercialization, enabling us tackle these challenges head-on.    Our cutting-edge facilities and expert teams support every stage - from process development and analytical method development through clinical manufacturing, tech transfer and onward to optimization and commercial manufacture. By offering high-quality, scalable manufacturing capabilities for monoclonal antibodies (mAbs), bispecifics (BsAbs), and other complex biologics, we ensure a robust and consistent manufacturing process that reduces risk, and speeds up time-to-market for your innovative therapies. Discover how Abzena can enhance and accelerate your manufacturing program today: https://lnkd.in/eHxGADyN #Biologics #Manufacturing #DrugDevelopment #CDMO

It's "Flashback Friday" featuring our San Diego facility tour event during #BIO last month. Guests were transported from the convention center to our state-of-the-art, clinical through commercial scale #biologics development and manufacturing facility in Sorrento Valley. Met with tasty beverages and appetizers, guests mingled with our #scientific and commercial leaders before heading on a tour of our process development and #analytical laboratories and #cGMP manufacturing suites. Thanks again to all who attended! If you're looking to scale-up your antibody program, come and take a tour and meet with our experts in San Diego today! For more information about our San Diego facilities, visit: https://lnkd.in/e9imbFnv #CDMO #CRO #DrugDevelopment #DrugSubstance